Literature DB >> 9140768

Determination of artemether and its metabolite, dihydroartemisinin, in plasma by high-performance liquid chromatography and electrochemical detection in the reductive mode.

N Sandrenan1, A Sioufi, J Godbillon, C Netter, M Donker, C van Valkenburg.   

Abstract

An analytical method for the determination of artemether (A) and its metabolite dihydroartemisinin (DHA) in human plasma has been developed and validated. The method is based on high-performance liquid chromatography (HPLC) and electrochemical detection in the reductive mode. A, DHA and artemisinin, the internal standard (I.S.), were extracted from plasma (1 ml) with 1-chlorobutane-isooctane (55:45, v/v). The solvent was transferred, evaporated to dryness under nitrogen and the residue dissolved in 600 microliters of water-ethyl alcohol (50:50, v/v). Chromatography was performed on a Nova-Pak CN, 4 microns analytical column (150 mm x 3.9 mm I.D.) at 35 degrees C. The mobile phase consisted of pH 5 acetate-acetonitrile (85:15, v/v) at a flow-rate of 1 ml/min. The analytes were detected by electrochemical detection in the reductive mode at a potential of -1.0 V. Intra-day accuracy and precision were assessed from the relative recoveries (found concentration in % of the nominal value) of spiked samples analysed on the same day (concentration range 10.9 to 202 ng/ml of A and 11.2 to 206 ng/ml of DHA in plasma). The mean recoveries over the entire concentration range were from 96 to 100% for A with C.V. from 6 to 13%, from 92% to 100% for DHA (alpha-tautomer) with C.V. from 4 to 16%. For A, the mean recovery was 96% at the limit of quantitation (LOQ) of 10.9 ng/ml with a C.V. of 13%. For DHA, the mean recovery was 100% at the LOQ of 11.2 ng/ml with a C.V. of 16%.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9140768     DOI: 10.1016/s0378-4347(96)00431-8

Source DB:  PubMed          Journal:  J Chromatogr B Biomed Sci Appl        ISSN: 1387-2273


  6 in total

1.  Population pharmacokinetics and therapeutic response of CGP 56697 (artemether + benflumetol) in malaria patients.

Authors:  F Ezzet; R Mull; J Karbwang
Journal:  Br J Clin Pharmacol       Date:  1998-12       Impact factor: 4.335

2.  Differential effects of orally versus parenterally administered qinghaosu derivative artemether in dogs.

Authors:  W Classen; B Altmann; P Gretener; C Souppart; P Skelton-Stroud; G Krinke
Journal:  Exp Toxicol Pathol       Date:  1999-11

Review 3.  Pharmacokinetics of artemisinin-type compounds.

Authors:  V Navaratnam; S M Mansor; N W Sit; J Grace; Q Li; P Olliaro
Journal:  Clin Pharmacokinet       Date:  2000-10       Impact factor: 6.447

4.  Plasmodium falciparum-based bioassay for measurement of artemisinin derivatives in plasma or serum.

Authors:  Paktiya Teja-Isavadharm; James O Peggins; Thomas G Brewer; Nicholas J White; H Kyle Webster; Dennis E Kyle
Journal:  Antimicrob Agents Chemother       Date:  2004-03       Impact factor: 5.191

Review 5.  Stereodynamic investigation of labile stereogenic centres in dihydroartemisinin.

Authors:  Ilaria D'Acquarica; Francesco Gasparrini; Dorina Kotoni; Marco Pierini; Claudio Villani; Walter Cabri; Michela Di Mattia; Fabrizio Giorgi
Journal:  Molecules       Date:  2010-03-05       Impact factor: 4.411

6.  Subchronic toxicological study of two artemisinin derivatives in dogs.

Authors:  Ji-ye Yin; He-mei Wang; Quan-jun Wang; Yan-sheng Dong; Gang Han; Yong-biao Guan; Ke-yong Zhao; Wen-sheng Qu; Ye Yuan; Xiao-xin Gao; Shu-fang Jing; Ri-gao Ding
Journal:  PLoS One       Date:  2014-04-16       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.